Impending crisis in provision of histopathology expertise for mouse functional genomics
Mark Twain, a skeptic of the idea of free will, argues in his essay “What Is Man?” that humans do not command their minds or the opinions they form. “You did not form that [opinion],” a speaker identified as “old man” says in the essay. “Your [mental] machinery did it for you-automatically and instantly, without
Full Post: Simple brain mechanisms explain arbitrary human visual decisions
The generation of new mouse models of human disease is accelerating rapidly due to the completion of whole-genome sequencing efforts and technological advances in the manipulation of the mouse genome.
The speed of progress in this endeavour has highlighted the shortage of experts to fully characterise the new mouse lines produced.
A European Commission (EC)-funded strategy initiative (PRIME) now reports a study on the provision of the specific pathology expertise in mouse functional genomics. The paper by Warren et al. reveals that in Europe there is a critical lack of the specific expertise needed to understand the pathology of mutant mice, and that much of the work is being carried out by pathologists in clinical diagnostic posts, often with little support or training in comparative pathology. Similar concerns have recently been voiced by pathologists in North America.
The results indicate a lack of both trainees and provision of specialist training in this field, with the availability of diagnostic expertise and advice falling far short of the number of genetically engineered mice (GEM) being generated for analysis. This has lead to the worrying trend of “DIY” pathology and the inaccurate reporting of pathological data in scientific journals.
The paper highlights the critical need for a coordinated approach to the specialist training of pathologists in laboratory mouse pathology and genetics, and the urgent need for investment in a training infrastructure for Europe.
A worldwide group of scientists has created an infectious prion disease in a mouse model, in a step that may help unravel the mystery of this progressive disease that affects the nervous system in humans and animals. The research team, including Christina J. Sigurdson, D.V.M., Ph.D., assistant professor of pathology at the University of California,
Full Post: Scientists create infectious prion disease in mouse model
There should be no barriers to providing high-quality speech pathology services, according to University of Queensland PhD graduate Dr Anne Hill. Completed through UQ’s School of Health and Rehabilitation Sciences, Dr Hill’s research found speech and language disorders could be validly and reliably assessed over the internet using a telerehabilitation application. “Having worked clinically with
Full Post: Speech and language disorders can be assessed over the internet
A new comprehensive online resource listing national expertise in the design and conduct of clinical trials is launched today. The UKCRC Registered Clinical Trials Units website provides, for the first time, centralised information on Clinical Trials Units (CTUs) in the UK - including the Bristol Randomised Trials Collaboration (BRTC) at the University of Bristol.
Full Post: New signpost to clinical trial expertise
Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children’s Research Hospital have alleviated sickle cell disease pathology. In their studies, the researchers found that the treated mice showed essentially no difference from normal mice. Although the scientists caution that applying the gene therapy to humans
Full Post: Gene therapy used to alleviate sickle cell disease pathology
Human and veterinary medicine could receive a big boost through use of larger animals, especially pigs and dogs, in research, with Europe at the forefront. There is the prospect of bringing drugs to the market more quickly at less cost, as well as accelerating progress in other forms of therapy, notably the use of
Full Post: Pigs and dogs can bridge gap between mice and humans in developing new therapies